The members of the first group are ANXA2R, ANXA4, ANXA8 and ANXA8L1, which were upregulated in RCC and higher expression correlated with worse clinical outcomes, indicating a pathogenic role in RCC. Here, ANXA8L1 is linked to renal cell carcinoma.